10-QPeriod: Q2 FY2005

CARDINAL HEALTH INC Quarterly Report for Q2 Ended Dec 31, 2004

Filed February 9, 2005For Securities:CAH

Summary

Cardinal Health Inc. (CAH) reported revenues of $18.6 billion for the three months ended December 31, 2004, a 13% increase year-over-year. However, the company experienced a significant 45% decline in operating earnings for the same period, reaching $320.8 million, largely due to substantial special items including restructuring costs and impairment charges, which totaled $103.1 million. The company is also undergoing various investigations by the SEC and U.S. Attorney's Office, leading to restatements of prior financial periods and disciplinary actions. Despite these challenges, the company continues to execute a global restructuring program aimed at improving efficiency and future profitability, with projected savings of $125 million in fiscal year 2005.

Key Highlights

  • 1Revenue increased by 13% to $18.6 billion for the three months ended December 31, 2004, compared to the prior year.
  • 2Operating earnings decreased by 45% to $320.8 million for the three months ended December 31, 2004, compared to the prior year, primarily impacted by special items.
  • 3The company incurred $103.1 million in special items during the quarter, including restructuring costs and merger-related expenses, partially offset by litigation settlements.
  • 4Significant asset impairments totaling $83.0 million were recorded during the quarter, impacting the Pharmaceutical Technologies and Services segment.
  • 5Cardinal Health is subject to ongoing investigations by the SEC and U.S. Attorney's Office, leading to prior period financial statement restatements.
  • 6A global restructuring program is underway, with Phase I expected to rationalize facilities and workforce, aiming for significant cost savings.
  • 7The company's Pharmaceutical Distribution business is transitioning to a fee-for-service model to address declining vendor margins.

Frequently Asked Questions

The significant decrease in operating earnings is primarily driven by substantial special items, including restructuring costs, merger-related expenses, and non-restructuring asset impairments. These items negatively impacted profitability during the quarter.

Cardinal Health is involved in formal investigations by the SEC and an inquiry by the U.S. Attorney's Office concerning accounting matters, including revenue classification and vitamin manufacturer recoveries. These investigations have led to restatements of prior financial statements and disciplinary actions for certain employees. The company continues to incur costs related to these investigations and reviews.

The company is transitioning its Pharmaceutical Distribution business to a fee-for-service model to counteract declining vendor margins. This involves establishing new distribution services agreements with branded pharmaceutical manufacturers to ensure adequate and predictable compensation for services rendered.

The global restructuring program aims to improve operational efficiency and customer value through business integration and a disciplined approach to resource allocation. Phase I is expected to result in facility rationalization and workforce reduction, with projected annual operating earnings improvements of $125 million in fiscal year 2005 and $200 million in fiscal year 2006.